Abstract

Osteoporosis, characterized by systemic impairment of bone mass and microarchitectural deterioration, represents a profound failure in the dynamic equilibrium of bone remodeling. This review synthesizes contemporary insights from biophysics and biochemistry to deconstruct the pathogenesis of osteoporosis into a hierarchical failure of molecular and cellular systems¹. We begin at the nanoscale, examining the altered compositional biochemistry of the bone matrix collagen cross-linking, non-collagenous protein signaling, and mineral crystal properties that fundamentally compromises material resilience.² We then ascend to the cellular scale, detailing the biochemical signaling cascades (RANKL/RANK/OPG, Wnt/β- catenin, sclerostin) that govern osteoclast and osteoblast activity, framing their dysregulation as a breakdown in communication networks³. Integrating these with biophysical principles, we explore how mechanosensing via osteocytic lacunocanalicular networks and integrin-mediated focal adhesions translates physical force into biochemical anabolic signals, and how this transduction is blunted in aging and disuse.4 The review emphasizes the concept of bone as a composite material, where osteoporosis-induced changes in mineral-to-collagen ratio, carbonate substitution, and collagen integrity degrade its inherent fracture resistance, quantified by parameters such as elastic modulus, toughness, and fatigue life.5 Finally, we discuss emerging diagnostic technologies leveraging these principles (e.g., Raman spectroscopy, nanoindentation) and novel therapeutic strategies targeting specific biochemical pathways (anti-sclerostin, cathepsin K inhibitors) and biophysical interventions (vibration therapy, electromagnetic field stimulation).6 This integrative perspective posits osteoporosis not merely as a quantitative loss of bone, but as a qualitative disintegration of a sophisticated biomaterial, guiding future research towards multi-scale, mechanism-based interventions.

• 1.   Seeman, E., & Delmas, P. D. Bone quality the material and structural basis of bone strength and fragility. N. Engl. J. Med. 354, 2250–2261 (2006).
• 2.   Sroga, G. E. & Vashishth, D. Effects of bone matrix proteins on fracture and fragility in osteoporosis. Curr. Osteoporos. Rep. 10, 141– 150 (2012).
• 3.   Baron, R. & Kneissel, M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat. Med. 19, 179–192 (2013).
• 4.   Robling, A. G. & Bonewald, L. F. The osteocyte: new insights. Annu. Rev. Physiol. 82, 485–506 (2020).
• 5.   Boskey, A. L. & Coleman, R. Aging and bone. J. Dent. Res. 89, 1333–1348 (2010).
• 6.   Khosla, S. & Hofbauer, L. C. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 5, 898–907 (2017).
• 7.   Clarke, B. Normal bone anatomy and physiology. Clin. J. Am. Soc. Nephrol. 3, S131–S139 (2008).
• 8.   Bonewald, L. F. The amazing osteocyte. J. Bone Miner. Res. 26, 229–238 (2011).
• 9.   Fratzl, P., Gupta, H. S., Paschalis, E. P. & Roschger, P. Structure and mechanical quality of the collagen–mineral nano-composite in bone. J. Mater. Chem. 14, 2115–2123 (2004).
• 10.   Shoulders, M. D. & Raines, R. T. Collagen structure and stability. Annu. Rev. Biochem. 78, 929–958 (2009).
• 11.   Yamauchi, M. & Sricholpech, M. Lysine posttranslational modifications of collagen. Essays Biochem. 52, 113–133 (2012).
• 12.   Vashishth, D. The role of the collagen matrix in skeletal fragility. Curr. Osteoporos. Rep. 5, 62–66 (2007).
• 13.   Fisher, L. W. & Fedarko, N. S. Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect. Tissue Res. 44, 33–40 (2003).
• 14.   Shea, M. K. & Booth, S. L. Role of vitamin K in the regulation of calcification. Int. Congr. Ser. 1297, 165–178 (2007).
• 15.   Grynpas, M. Age and disease-related changes in the mineral of bone. Calcif. Tissue Int. 53, S57-S64 (1993).
• 16.   Rubin, M. A. et al. TEM analysis of the nanostructure of normal and osteoporotic human trabecular bone. Bone 33, 270–282 (2003).
• 17.   Paschalis, E. P. et al. FTIR microspectroscopic analysis of human osteonal bone. Calcif. Tissue Int. 59, 480–487 (1996).
• 18.   Roschger, P. et al. Bone mineralization density distribution in health and disease. Bone 42, 456–466 (2008).
• 9.   Raisz, L. G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest. 115, 3318–3325 (2005).
• 20.   Lacey, D. L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165–176 (1998).
• 21.   Weitzmann, M. N. & Pacifici, R. Estrogen deficiency and bone loss: an inflammatory tale. J. Clin. Invest. 116, 1186–1194 (2006).
• 22.   Takayanagi, H. et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889– 901 (2002).
• 23.   Simonet, W. S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309–319 (1997).
• 24.   Hofbauer, L. C. et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. 15, 2–12 (2000).
• 25.   Riggs, B. L., Khosla, S. & Melton, L. J. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23, 279–302 (2002).
• 26.   Compton, J. Glucocorticoid-induced osteoporosis: an update. Endocrine 61, 7–16 (2018).
• 27.   Baron, R. & Rawadi, G. Targeting the Wnt/β- catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148, 2635–2643 (2007).
• 28.   Lin, C. et al. Sclerostin-mediated regulation of bone remodeling: recent advances and therapeutic implications. Nat. Rev. Endocrinol. 20, 145–162 (2024).
• 29.   Neer, R. M. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434–1441 (2001).
• 30.   Silva, B. C. & Bilezikian, J. P. Parathyroid hormone: anabolic and catabolic actions on the skeleton. Curr. Opin. Pharmacol. 22, 41–50 (2015).
• 31.   Vanderschueren, D. et al. Sex steroid actions in male bone. Endocr. Rev. 35, 906–960 (2014).
• 32.   Wolff, J. The Law of Bone Remodelling. (Springer, 1986).
• 33.   Weinbaum, S., Cowin, S. C. & Zeng, Y. A model for the excitation of osteocytes by mechanical loading-induced bone fluid shear stresses. J. Biomech. 27, 339–360 (1994).
• 34.   McNamara, L. M., Majeska, R. J., Weinbaum, S., Friedrich, V. & Schaffler, M. B. Attachment of osteocyte cell processes to the bone matrix. Anat. Rec. 292, 355–363 (2009).
• 35.   Sun, W. et al. The mechanosensitive Piezo1 channel is required for bone formation. eLife 8, e47454 (2019).
• 36.   Malone, A. M. et al. Primary cilia mediate mechanosensing in bone cells by a calciumindependent mechanism. Proc. Natl. Acad. Sci. U.S.A. 104, 13325–13330 (2007).
• 37.   Klein-Nulend, J., van der Plas, A., Semeins, C. M., Ajubi, N. E., Frangos, J. A., Nijweide, P. J. & Burger, E. H. Sensitivity of osteocytes to biomechanical stress in vitro. FASEB J. 9, 441–445 (1995).
• 38.   Nakashima, T. et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 17, 1231–1234 (2011).
• 39.   Currey, J. D. The many adaptations of bone. J. Biomech. 36, 1487–1495 (2003).
• 40.   Drake, M. T., Clarke, B. L. & Khosla, S. Cathepsin K inhibitors for osteoporosis: biology, potential clinical utility, and lessons learned. Endocr. Rev. 38, 325–350 (2017).
• 41.   Burr, D. B. et al. Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J. Bone Miner. Res. 12, 6–15 (1997).
• 42.   Jilka, R. L. & O’Brien, C. A. The role of osteocytes in age-related bone loss. Curr. Osteoporos. Rep. 14, 16–25 (2016).
• 43.   Tang, Y. et al. TGF-β1–induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15, 757–765 (2009).
• 44.   Burghardt, A. J., Link, T. M. & Majumdar, S. High-resolution computed tomography for clinical imaging of bone microarchitecture. Clin. Orthop. Relat. Res. 469, 2179–2193 (2011).
• 45.   Vasikaran, S. et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos. Int. 22, 391–420 (2011).
• 46.   Diez-Perez, A. et al. Microindentation for in vivo measurement of bone tissue mechanical properties in humans. J. Bone Miner. Res. 25, 1877–1885 (2010).
• 47.   Black, D. M. & Rosen, C. J. Clinical Practice. Postmenopausal Osteoporosis. N. Engl. J. Med. 374, 254–262 (2016).
• 48.   Bassett, C. A. L. Beneficial effects of electromagnetic fields. J. Cell. Biochem. 51, 387–393 (1993).

Data Sharing Statement

Funding